Waverly Advisors LLC Has $12.45 Million Holdings in Abbott Laboratories $ABT

Waverly Advisors LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 7.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 137,186 shares of the healthcare product maker’s stock after buying an additional 9,132 shares during the period. Waverly Advisors LLC’s holdings in Abbott Laboratories were worth $12,448,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ABT. Nia Impact Advisors LLC boosted its holdings in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. Riggs Asset Managment Co. Inc. grew its holdings in shares of Abbott Laboratories by 9.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after purchasing an additional 88 shares during the last quarter. Eley Financial Management Inc increased its position in Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares in the last quarter. Copley Financial Group Inc. increased its holdings in shares of Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock valued at $556,000 after purchasing an additional 93 shares in the last quarter. Finally, Kelleher Financial Advisors raised its position in shares of Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after acquiring an additional 93 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating challenging cases of atrial fibrillation. The catheter combines pulsed-field ablation (PFA) and radiofrequency (RF) energy, giving physicians greater flexibility and expanding Abbott’s cardiac rhythm-management portfolio. The device previously received a European CE mark in January 2026, and U.S. approval could support broader adoption and future revenue growth. Abbott’s dual ablation catheter lands FDA approval
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating on Abbott and maintained a $135 price target, indicating substantial potential upside from recent trading levels. The endorsement suggests the firm views Abbott’s product pipeline and long-term fundamentals favorably. TD Cowen reaffirms Abbott buy rating
• Neutral Sentiment: A comparison of Abbott and Envista focuses on which medical-products stock offers better value. Abbott’s established business and growth prospects remain attractive, but its valuation may make it less compelling to investors specifically seeking undervalued shares. NVST or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Abbott was highlighted as a potential defensive “Dividend King,” supported by a 54-year dividend-growth streak and healthcare-related catalysts. This may appeal to income-focused investors, although the article is general commentary rather than a new company announcement. If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King
• Negative Sentiment: Abbott recently underperformed the broader market in a prior session, reflecting near-term selling pressure. The decline appears market- or sentiment-driven rather than tied to a deterioration in the company’s fundamentals, but it may be tempering the immediate reaction to the FDA news. Here’s Why Abbott Fell More Than the Broader Market

Abbott Laboratories Price Performance

NYSE:ABT opened at $105.29 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The firm’s 50-day simple moving average is $105.30 and its 200 day simple moving average is $99.90. The firm has a market cap of $182.19 billion, a price-to-earnings ratio of 34.07, a P/E/G ratio of 1.96 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Citigroup boosted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, UBS Group decreased their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.